StreetInsider.com News Articles

Form 8-K VOLITIONRX LTD For: Jun 17

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667079.html

Form 8-K VOLITIONRX LTD For: Jun 17

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667079.html

Maxim Group Resumes VolitionRX (VNRX) at Buy

Thu, 18 Jun 2026 07:55:02 -0400

Maxim Group analyst Michael Okunewitch resumes coverage on VolitionRX (NYSE: VNRX) with a Buy rating and a price target of $4.00.

For an analyst ratings summary and ratings history on VolitionRX click here. For more ratings news on VolitionRX click here.

Shares of VolitionRX closed at $1.37 yesterday.

VolitionRx and Sysmex partner to optimize NETs diagnostic assay

Wed, 17 Jun 2026 08:16:03 -0400

VolitionRx Limited (NYSE American: VNRX) has announced a collaboration with Sysmex Corporation (TYO: 6869) to optimize Volition's Nu.Q NETs H3.1 assay on the Sysmex diagnostic platform, according to a press release from the Henderson, Nevada-based company.

The agreement follows what Volition describes as a successful transfer of the Nu.Q NETs assay onto Sysmex's platform. The collaboration will now move into an optimization phase focused on diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases.

Sysmex, headquartered in Kobe, Japan, operates in the field of in vitro diagnostics across more than 190 countries. Volition's Chief

VolitionRx Announces Collaboration with Sysmex

Wed, 17 Jun 2026 08:15:00 -0400

HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.

Gael Forterre, Chief Commercial Officer, Volition commented:

"We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development,

VolitionRx Announces Collaboration with Sysmex

Wed, 17 Jun 2026 08:15:00 -0400

Gael Forterre, Chief Commercial Officer, Volition commented:

VolitionRx Announces Collaboration with Sysmex

Wed, 17 Jun 2026 08:15:00 -0400

Gael Forterre, Chief Commercial Officer, Volition commented:

VolitionRx Announces Collaboration with Sysmex

Wed, 17 Jun 2026 08:15:00 -0400

Gael Forterre, Chief Commercial Officer, Volition commented:

Form 8-K VOLITIONRX LTD For: Jun 07

Wed, 10 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260610/26626035.html

Form 8-K VOLITIONRX LTD For: Jun 07

Wed, 10 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260610/26626035.html

Form 424B5 VOLITIONRX LTD

Tue, 09 Jun 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260609/26621638.html

Form 424B5 VOLITIONRX LTD

Tue, 09 Jun 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20260609/26621638.html

VolitionRx prices $4.6 million stock offering at $1.55 per share

Sun, 07 Jun 2026 18:30:16 -0400

VolitionRx Limited (NYSE AMERICAN: VNRX) announced the pricing of its public offering of 2,960,000 shares of common stock and warrants to purchase up to 1,480,000 shares at a combined price of $1.55 per share and accompanying half warrant.

The epigenetics company expects gross proceeds of approximately $4.6 million before deducting placement agent fees and other offering expenses. Each warrant carries an exercise price of $1.55 per share, becomes exercisable immediately upon issuance, and expires five years after issuance. If all warrants are exercised on a cash basis, the company could receive an additional $2.3 million in gross proceeds.

Maxim Group LLC serves

VolitionRx prices $4.6 million stock offering at $1.55 per share

Sun, 07 Jun 2026 18:30:16 -0400

Maxim Group LLC serves

VolitionRx prices $4.6 million stock offering at $1.55 per share

Sun, 07 Jun 2026 18:30:16 -0400

Maxim Group LLC serves

VolitionRx prices $4.6 million stock offering at $1.55 per share

Sun, 07 Jun 2026 18:30:16 -0400

Maxim Group LLC serves

VolitionRx Announces Pricing of $4.6 Million Public Offering